NFKB1 and diabetic kidney disease: serum FTO level was decreased in DKD patients (72, 90), whereas the expression of FTO was increased in high glucose-induced podocytes, and FTO upregulation enhanced serum amyloid A2 mRNA stability by regulating the NF-κB pathway, thus participating in podocyte injury and the progression of DKD (127).